PMID- 36089781
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230623
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 23
IP  - 4
DP  - 2023
TI  - Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus 
      Erythematosus.
PG  - 503-514
LID - 10.2174/1871530322666220908154253 [doi]
AB  - Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
      damage to multiple systems and a higher risk of cardiovascular disease. In 
      addition, several studies have found that insulin resistance (IR) is more 
      prevalent in SLE patients than controls, increasing the risk of prediabetes, type 
      2 diabetes mellitus (T2DM) and morbidity. The objective of this review article 
      was to summarize the most relevant evidence about the relationship among IR, T2DM 
      and SLE, including the effects of proinflammatory states, acute-phase proteins, 
      pro-inflammatory cytokines, and pharmacological SLE treatment. A better 
      understanding of the mechanisms involved in these comorbidities will allow better 
      treatment strategies.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Garcia-Carrasco, Mario
AU  - Garcia-Carrasco M
AD  - Department of Rheumatology, Medicine School, Meritorious Autonomous University of 
      Puebla, Puebla, Mexico.
FAU - Mendoza-Pinto, Claudia
AU  - Mendoza-Pinto C
AD  - Department of Rheumatology, Medicine School, Meritorious Autonomous University of 
      Puebla, Puebla, Mexico.
AD  - Systemic Autoimmune Diseases Research Unit, Specialties Hospital UMAE, Mexican 
      Social Security Institute, Puebla, Mexico.
FAU - Munguia-Realpozo, Pamela
AU  - Munguia-Realpozo P
AD  - Department of Rheumatology, Medicine School, Meritorious Autonomous University of 
      Puebla, Puebla, Mexico.
FAU - Etchegaray-Morales, Ivet
AU  - Etchegaray-Morales I
AD  - Department of Rheumatology, Medicine School, Meritorious Autonomous University of 
      Puebla, Puebla, Mexico.
FAU - Velez-Pelcastre, Sandra Karina
AU  - Velez-Pelcastre SK
AD  - Department of Rheumatology, Medicine School, Meritorious Autonomous University of 
      Puebla, Puebla, Mexico.
FAU - Mendez-Martinez, Socorro
AU  - Mendez-Martinez S
AD  - Research in Health Coordination, Mexican Social Security Institute, Puebla, 
      Mexico.
FAU - Zamora-Ginez, Irma
AU  - Zamora-Ginez I
AD  - Coordination of the Master's degree in Medical Sciences and Research, Medicine 
      School, Meritorious Autonomous University of Puebla, Puebla, Mexico.
FAU - de Lara, Luis Guillermo Vazquez
AU  - de Lara LGV
AD  - Laboratory of Experimental Medicine, Medicine School, Meritorious Autonomous 
      University of Puebla, Puebla, Mexico.
FAU - Galvez-Romero, Jose Luis
AU  - Galvez-Romero JL
AD  - Research Department, Hospital Regional, Instituto de Seguridad y Servicios 
      Sociales de los Trabajadores del Estado, Puebla, Mexico.
FAU - Escamilla-Marquez, Marco
AU  - Escamilla-Marquez M
AD  - Department of Endocrinology, Medicine School, Meritorious Autonomous University 
      of Puebla, Puebla, Mexico.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
SB  - IM
MH  - Humans
MH  - *Insulin Resistance
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - *Lupus Erythematosus, Systemic/complications/diagnosis/drug therapy
MH  - *Cardiovascular Diseases
MH  - Comorbidity
OTO - NOTNLM
OT  - Systemic lupus erythematosus
OT  - T2DM
OT  - autoimmune disease
OT  - diabetes mellitus
OT  - insulin resistance
OT  - prediabetes
EDAT- 2022/09/13 06:00
MHDA- 2023/05/22 06:42
CRDT- 2022/09/12 02:07
PHST- 2022/04/07 00:00 [received]
PHST- 2022/06/14 00:00 [revised]
PHST- 2022/06/21 00:00 [accepted]
PHST- 2023/05/22 06:42 [medline]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/12 02:07 [entrez]
AID - EMIDDT-EPUB-126243 [pii]
AID - 10.2174/1871530322666220908154253 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2023;23(4):503-514. doi: 
      10.2174/1871530322666220908154253.